Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: a discrete choice experiment.

CONCLUSIONS: Severe SE, not outcomes, was the most decisive attribute determining future HCRCT participation. Particular attention should be paid to providing clear information, in particular on severe SE, to potential participants. Immunotherapy would appear to be the best HCRCT candidate for both PLWH and physicians. However, if the risk of cancer could be avoided, gene therapy would become the preferred strategy for the latter and the second choice for the former. PMID: 32077248 [PubMed - in process]
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research

Related Links:

Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News CDC’s COVID-19 Guidance for Dental Settings  Dental health care personnel can find COVID-19-related information on the CDC’s Division of Oral Health website, which offers guidance and resources for clinics and health care facilities and recommen...
Source: NIDCR Science News - Category: Dentistry Source Type: news
The President has proposed a $38.7 billion budget for the National Institutes of Health in fiscal year (FY) 2021. This translates to a $3 billion or 7 percent cut in the agency’s funding compared to FY 2020. The NIH budget request includes a $50 million initiative to use artificial intelligence (AI) to develop a better understanding of the causes of chronic diseases and to identify early treatments. This plan is in line with the Administration’s “Industries of the Future” effort, which supports using and developing AI across sectors. The budget would provide $50 million for the Childhood Cancer ...
Source: Public Policy Reports - Category: Biology Authors: Source Type: news
Publication date: Available online 15 September 2019Source: The Lancet HIVAuthor(s): Joseph Kagaayi, Larry W Chang, Victor Ssempijja, M Kate Grabowski, Robert Ssekubugu, Gertrude Nakigozi, Godfrey Kigozi, David M Serwadda, Ronald H Gray, Fred Nalugoda, Nelson K Sew.ambo, Lisa Nelson, Lisa A Mills, Donna Kabatesi, Stella Alamo, Caitlin E Kennedy, Aaron A R Tobian, John S Santelli, Anna Mia Ekström, Helena NordenstedtSummaryBackgroundTargeting combination HIV interventions to locations and populations with high HIV burden is a global priority, but the impact of these strategies on HIV incidence is unclear. We assessed t...
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research
Vascular events, infections, cancers account for 74.1 percent of high - severity misdiagnosis - related harms
Source: The Doctors Lounge - Psychiatry - Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Ophthalmology, Orthopedics, ENT, Source Type: news
Joanna Mikulak1,2, Elena Bruni1,2, Ferdinando Oriolo1,2, Clara Di Vito1 and Domenico Mavilio1,2* 1Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Milan, Italy 2Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy The liver is considered a preferential tissue for NK cells residency. In humans, almost 50% of all intrahepatic lymphocytes are NK cells that are strongly imprinted in a liver-specific manner and show a broad spectrum of cellular heterogeneity. Hepatic NK (he-NK) cells play key roles in tuning liver immune response in b...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Andrew R. Crowley1 and Margaret E. Ackerman1,2* 1Molecular and Cellular Biology Program, Dartmouth College, Hanover, NH, United States2Thayer School of Engineering, Dartmouth College, Hanover, NH, United States The field of HIV research relies heavily on non-human primates, particularly the members of the macaque genus, as models for the evaluation of candidate vaccines and monoclonal antibodies. A growing body of research suggests that successful protection of humans will not solely rely on the neutralization activity of an antibody's antigen binding fragment. Rather, immunological effector functions pro...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
The National Institutes of Health (NIH) would receive $34.4 billion in FY 2020, roughly $4.7 billion or 13 percent below the levels enacted by Congress for FY 2019, according to the President’s Budget released on March 11. The budget for NIH includes $492 million in funding made available through the 21st Century Cures Act and $150 million in mandatory funding. The leading biomedical research agency in the world would receive budget cuts across the board. All NIH centers are slated for budget reductions: National Cancer Institute: -8.7 percent National Heart, Lung, and Blood Institute: -14 percent National Inst...
Source: Public Policy Reports - Category: Biology Authors: Source Type: news
A man in London has become only the second person to achieve remission from HIV infection, researchers from the UK reported Tuesday. The therapy responsible has worked on only one other person who is considered to be “cured” of HIV: Timothy Ray Brown, who still does not show signs of the virus in his body after more than 10 years. Here’s what to know about the landmark case. How did it happen? In a letter published in the journal Nature, researchers led by Ravindra Gupta from the University of Cambridge London and Imperial College London and his colleagues say that they used a treatment similar to the one...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized HIV/AIDS Source Type: news
About 1.1 million Americans currently live with HIV, and approximately 40,000 are infected each year, according to federal data. But in his State of the Union address, President Donald Trump promised to “eliminate the HIV epidemic in the United States within 10 years” — a plan that hinges on a multi-agency push for better diagnosis, treatment and prevention in at-risk communities, health officials said Wednesday. Trump introduced the plan during his annual address on Tuesday but offered few details. Health officials fleshed out the plan during a call with reporters on Wednesday. The initiative will be ove...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized healthytime HIV/AIDS onetime Source Type: news
More News: Allergy | Allergy & Immunology | Cancer | Cancer & Oncology | Clinical Trials | France Health | Gene Therapy | Genetics | HIV AIDS | Immunotherapy | Infectious Diseases | Medical Ethics | Study